Clinical Trials

A biotech firm's novel marine compound, now patented, shows promise in modulating key cell pathways, offering a new strategy against intractable diseases.

Amid promising safety signals, Kazia Therapeutics expands its trial for paxalisib in TNBC, a strategic move offering new hope for a hard-to-treat cancer.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

Pliant Therapeutics heads to ASCO with data on a novel drug designed to reawaken the immune system's attack on advanced, treatment-resistant tumors.

New data shows Moleculin Biotech's Annamycin avoids heart toxicity, a breakthrough that could transform treatment for leukemia and sarcoma patients.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

Central Ohio cancer patients gain unprecedented access to advanced therapies and clinical trials as Zangmeister Cancer Center joins OSU's James Cancer Network.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.

By hiring a third former FDA oncology leader, Precision for Medicine creates an unparalleled regulatory brain trust to speed up cancer drug approvals.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

Paris-based Ennov lands a major transatlantic investment to accelerate its AI platform, aiming to reshape global drug development and regulatory processes.

A novel drug is in clinical trials for depression, moving beyond neurotransmitters to target the brain's fundamental energy production and repair mechanisms.

A new clinical trial is testing a device that uses electricity to deliver chemo directly into tumors, a strategy that could revolutionize treatment.

IGI announces ISB 2301, a first-in-class antibody targeting three tumor antigens and activating both T and NK cells for a new assault on solid tumors.

Mispro's new contract vivarium at Genesis Science Center aims to provide crucial, flexible lab space for San Diego's burgeoning biotech startups.

A new purpose-built lab, Toronto's first in 20 years, attracts a major cell therapy firm, signaling a turning point for Canada's life sciences sector.

A first-in-class drug for anxiety has entered patient trials, offering a novel approach that could reshape mental healthcare for millions.

Led by OrbiMed, the financing will propel Accro's promising oral RIPK2 inhibitor for Ulcerative Colitis into a pivotal Phase IIb clinical trial.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

Renowned cancer researcher Dr. Dario Altieri leaves a top CEO post to return to the lab at Jefferson, signaling a major shift in Philadelphia's science scene.